anti-CD38-CAR-TCRz/4-1BB-expressing T lymphocytes

A preparation of genetically modified T lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 38 (CD38) that is linked to tandem costimulatory domains of the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3z) and 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD38-CAR-TCRz/4-1BB-expressing T lymphocytes are directed to and induce selective toxicity in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.